Neurotrope, Inc. (NASDAQ: NTRP) Starts Presentation at the 2017 Marcum Microcap Conference
Neurotrope (NASDAQ: NTRP) is developing a novel therapy to treat and potentially reverse moderate to severe Alzheimer's dementia and other neurodegenerative diseases. The scientific basis of the treatment is activation of Protein Kinase C isozymes ε and α by Bryostatin-1, a natural product, which in mouse Alzheimer's disease models was demonstrated to result in repair of damaged synapses as well as synaptogenesis, the induction of new neuronal networks, reduction of toxic beta-amyloid generation, prevention of neuronal death, and enhancement of memory and learning, thus having the potential to improve cognition and behavior in Alzheimer's dementia. For more information, visit the…
